679 reports of this reaction
1.3% of all ISOSORBIDE MONONITRATE reports
#19 most reported adverse reaction
DEHYDRATION is the #19 most commonly reported adverse reaction for ISOSORBIDE MONONITRATE, manufactured by ANI Pharmaceuticals, Inc.. There are 679 FDA adverse event reports linking ISOSORBIDE MONONITRATE to DEHYDRATION. This represents approximately 1.3% of all 53,965 adverse event reports for this drug.
Patients taking ISOSORBIDE MONONITRATE who experience dehydration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEHYDRATION is a less commonly reported adverse event for ISOSORBIDE MONONITRATE, but still significant enough to appear in the safety profile.
In addition to dehydration, the following adverse reactions have been reported for ISOSORBIDE MONONITRATE:
The following drugs have also been linked to dehydration in FDA adverse event reports:
DEHYDRATION has been reported as an adverse event in 679 FDA reports for ISOSORBIDE MONONITRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEHYDRATION accounts for approximately 1.3% of all adverse event reports for ISOSORBIDE MONONITRATE, making it a notable side effect.
If you experience dehydration while taking ISOSORBIDE MONONITRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.